within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07A_IntestinalAntiinfectives.A07AA12_Fidaxomicin;

model Fidaxomicin
  extends Pharmacolibrary.Drugs.ATC.A.A07AA12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A07AA12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fidaxomicin is a narrow-spectrum macrocyclic antibiotic used primarily for the treatment of Clostridioides difficile-associated diarrhea. It is approved for use in adults and children and exhibits minimal systemic absorption, acting mainly in the gastrointestinal tract.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Louie, TJ, et al., &amp; Shue, YK (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. <i>The New England journal of medicine</i> 364(5) 422–431. DOI:<a href=\"https://doi.org/10.1056/NEJMoa0910812\">10.1056/NEJMoa0910812</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21288078/\">https://pubmed.ncbi.nlm.nih.gov/21288078</a></p></li><li><p>Tashiro, S, et al., &amp; Matsumoto, K (2023). Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models. <i>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</i> 29(5) 616–622. DOI:<a href=\"https://doi.org/10.1016/j.cmi.2022.12.015\">10.1016/j.cmi.2022.12.015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36574949/\">https://pubmed.ncbi.nlm.nih.gov/36574949</a></p></li><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2015). Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection. <i>The Canadian journal of infectious diseases &amp; medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale</i> 26(6) 305–312. DOI:<a href=\"https://doi.org/10.1155/2015/934594\">10.1155/2015/934594</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26744587/\">https://pubmed.ncbi.nlm.nih.gov/26744587</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fidaxomicin;
